Pulmonary large cell carcinoma, highly positive for PD‐L1, shows marked response to pembrolizumab: A case report

Pulmonary large cell carcinoma, highly positive for PD‐L1, shows marked response to pembrolizumab: A case report

Abstract Pulmonary large cell carcinoma (LCC) is classified as a poorly defined entity among non‐small cell lung cancers (NSCLCs). At present, there are no effective anticancer drugs, such as molecular targeted drugs, for LCC, and it has been reported that patient prognosis is poor. Recently, the de...

Full description

Bibliographic Details
Main Authors:	Naoyuki Okabe, Hayato Mine, Hironori Takagi, Masayuki Watanabe, Satoshi Muto, Yuki Matsumura, Yutaka Shio, Hiroyuki Suzuki
Format:	Article
Language:	English
Published:	Wiley 2021-04-01
Series:	Thoracic Cancer
Subjects:	immunotherapy large cell carcinoma lung PD‐L1 pembrolizumab
Online Access:	https://doi.org/10.1111/1759-7714.13850

Similar Items

Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression
by: Takuma Isshiki, et al.
Published: (2018-10-01)

Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
by: Nicolas A. Giraldo, et al.
Published: (2018-10-01)

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer
by: Janice M. Mehnert, et al.
Published: (2019-03-01)

PEMBROLIZUMAB IN THE TREATMENT OF METASTATIC MELANOMA
by: I. V. SAMOILENKO, et al.
Published: (2017-06-01)

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data
by: Elizabeth Dudnik, et al.
Published: (2021-01-01)

The Combined Use of Chemotherapy and Radiotherapy with PD-1 Inhibitor, Pembrolizumab, in Advanced Cervical Cancer: A Case Report
by: Lyu M, et al.
Published: (2020-05-01)

A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab
by: Sugano T, et al.
Published: (2018-09-01)

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
by: Xin Li, et al.
Published: (2018-01-01)

Exceptionally rapid response to pembrolizumab in a SMARCA4‐deficient thoracic sarcoma overexpressing PD‐L1: A case report
by: Kohichi Takada, et al.
Published: (2019-12-01)

Sustained response to pembrolizumab in recurrent perivascular epithelioid cell tumor with elevated expression of programmed death ligand: a case report
by: Ali McBride, et al.
Published: (2021-07-01)

Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC
by: Ning Wan, et al.
Published: (2020-03-01)

Pembrolizumab‐induced sarcoid granulomatous panniculitis and bullous pemphigoid in a single patient
by: Anthony D. Honigman, et al.
Published: (2019-04-01)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
by: Inokuchi J, et al.
Published: (2019-05-01)

Monitoring antibody binding to T cells in a pembrolizumab‐treated patient with lung adenocarcinoma on hemodialysis
by: Akio Osa, et al.
Published: (2019-11-01)

Case report: Bilateral uveitis and papillitis secondary to treatment with pembrolizumab
by: Carmen Navarro-Perea, et al.
Published: (2019-01-01)

Targeting the PD-1/PD-L1 axis in the treatment of lung cancer
by: Matikas Alexios, et al.
Published: (2016-03-01)

Metastatic cervical cancer: clinical experience with pembrolizumab application. Case report
by: Anna E. Protasova, et al.
Published: (2021-08-01)

Pembrolizumab-Induced Thyroiditis Shows PD-L1Expressing Histiocytes and Infiltrating T Cells in Thyroid Tissue - A Case Report
by: Jörg Jabkowski, et al.
Published: (2021-06-01)

New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab
by: Bylicki O, et al.
Published: (2018-07-01)

Endoscopic central airway recanalization to enable first line pembrolizumab treatment in a PD-L1 strongly positive non-small cell lung cancer: a case report
by: Alfonso Fiorelli, et al.
Published: (2019-03-01)

Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data
by: du Rusquec P, et al.
Published: (2019-05-01)

Response of Metastatic Chordoma to the Immune Checkpoint Inhibitor Pembrolizumab: A Case Report
by: Xiaoli Wu, et al.
Published: (2020-12-01)

Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas
by: Camilo Jimenez, et al.
Published: (2020-08-01)

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
by: Tomas Jelinek, et al.
Published: (2018-11-01)

A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies
by: Qu J, et al.
Published: (2020-07-01)

Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report
by: Kazumi Nishino, et al.
Published: (2020-04-01)

Olaparib and Pembrolizumab Treatment for BRCA1-Mutated and PD-L1-Positive Intrahepatic Cholangiocarcinoma Recurrence and Metastasis: A Case Report
by: Xiong F, et al.
Published: (2020-07-01)

Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma
by: Evidio Domingo-Musibay, et al.
Published: (2018-06-01)

Monitoring Patient Response to Pembrolizumab With Peripheral Blood Exhaustion Marker Profiles
by: Moira Graves, et al.
Published: (2019-05-01)

Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma
by: Ester Simeone, et al.
Published: (2017-03-01)

An extrauterine extensively metastatic epithelioid trophoblastic tumor responsive to pembrolizumab
by: Sarah G. Bell, et al.
Published: (2021-08-01)

Evidence to Date: Evaluating Pembrolizumab in the Treatment of Extensive-Stage Small-Cell Lung Cancer
by: Ivy Riano, et al.
Published: (2021-07-01)

Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
by: Ya Chen, et al.
Published: (2021-06-01)

Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report
by: Chia-Yi Tian, et al.
Published: (2021-04-01)

Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives
by: Yating Zhao, et al.
Published: (2021-07-01)

A severe case of neuro-Sjögren’s syndrome induced by pembrolizumab
by: Jaqueline Ghosn, et al.
Published: (2018-10-01)

Pembrolizumab‐induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer
by: Maki Todo, et al.
Published: (2020-01-01)

Successful treatment of recurrent unresectable squamous cell carcinoma of the head and neck using pembrolizumab
by: A. M. Mudunov, et al.
Published: (2019-04-01)

Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population
by: Tamkin Ahmadzada, BE, et al.
Published: (2020-11-01)

Pembrolizumab in a Patient With Heavily Pre-Treated Squamous Cell Thymic Carcinoma and Cardiac Impairment: A Case Report and Literature Review
by: Alessandro Cafaro, et al.
Published: (2020-08-01)